Ulster University researchers found that mercury exposure through dental fillings or the consumption of seafood does not exacerbate symptoms of systemic lupus erythematous (SLE). While there is a lack of scientific evidence, exposure to mercury is widely believed to trigger SLE in patients who are genetically susceptible. In…
Temple University School of Medicine researchers have discovered how infections cause lupus flares. In a study funded by the Lupus Research Institute (LRI) and the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Stefania Galluci, PhD, and her team identified a mechanism through which a specific type…
Immunovia AB, together with Lund University in Sweden, will launch a new program to develop, validate, and commercialize antibody array-based tests for differential diagnostics and for prediction and monitoring of systemic lupus erythematosus (SLE) flares. SLE is one of the hardest diseases to diagnose as its symptoms are similar to those…
Systemic lupus erythematosus (SLE) patients with chronic renal failure who are using anticoagulants or antiepileptics are at higher risk for osteoporosis and fragility fractures, according to a study, “Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus,” published in the journal Lupus Science…
Resolve Therapeutics has successfully completed a dose escalation study of its candidate drug RSLV-132 targeting systemic lupus erythematosus (SLE). RSLV-132 works by breaking down the RNA found in immune complexes. Increasing evidence shows the importance of RNA bound to autoantibody immune complexes to activate the inflammatory pathway regulated by interferon. The drug…
A recent study found it is possible to distinguish systemic lupus erythematosus (SLE) patients from those with primary fibromyalgia (FM), with complete specificity, using a new test measuring the levels of abundant proteins in circulation. The study, “Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound…
XTL Biopharmaceuticals Ltd. announced it accepted an invitation to join Lupus Foundation of America (LFA)’s Corporate Advisory Council (CAC). XTL is a clinical-stage biotech dedicated to developing pharmaceutical products to treat autoimmune diseases such as lupus. The biotech’s lead drug candidate, hCDR1, is a top-quality clinical asset for the…
Aurinia Pharmaceuticals has completed the initial analysis of voclosporin in its AURION trial, an open label, single arm, exploratory trial examining patients with active lupus nephritis (LN) taking voclosporin 23.7 mg. twice daily in combination with standard of care, mycophenolate mofetil, and corticosteroids. The study is assessing biomarkers of disease…
Research conducted on medical records from over a quarter million adult patients found that African-Americans with connective tissue diseases were twice as likely to suffer complications that increase the risk of a heart attack, stroke, or death. The study, “The Prevalence of Atherosclerosis in Those with…
Lupus patients are more likely to have high levels of prothrombotic antibodies that interact with cell membrane phospholipids (PLs), which are thought to be a possible cause of maternal morbidity. Now, researchers have identified a specific antiphospholipid antibody (aPL) that appears to predict the likelihood of pregnancy complications. The study, “Lupus anticoagulant is…